APVO vs PATH · rev $3.1M vs P/E 19, rev $1.61B
Aptevo Therapeutics Inc (APVO) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Aptevo Therapeutics Inc (APVO) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported APVO revenue for 2022-12-31 was $3.1M. Net income was $8.0M. APVO currently screens at market cap $9.9M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
APVO currently screens at market cap $9.9M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the APVO and PATH stock pages for the full models.
Not investment advice.